Caprenin is a triglyceride that contains primarily caprylic (C8:0), capric (ClO:O), and behenic (C22:O) acids and modest amounts of arachidic (C20:O) and lignoceric (C24:O) acids. Using the fat-balance technique, the absorption of C20:0, C22:0, and C24:O was measured in 20 healthy adult men and women aged 20-60 years consuming a chocolate-flavored caprenin confection. The absorption values for these very long-chain fatty acids (VLCFAs) were determined based on measurements of their dietary intake and fecal excretion during a 5-day treatment period and a 7-day posttreatment washout period after correcting for baseline excretion of VLCFAs. Each subject consumed 4.7 g C20:0,52.8 g C22:0, and 0.84 g C24:O from the test confection during the treatment. Absorption averaged 41.6% ? 3.6% (SEM) for C20:0,28.8% t 4.4% for C22:0, and 14.8% ? 3.9% for C24:O. Using a modification of the Atwater method, the physiological fuel value (caloric value) of caprenin was then calculated. This modified method takes into account the partial absorption of VLCFAs and the heat loss due to the metabolism of the medium-chain fatty acids C8:O and C1O:O. The results of this study demonstrate that the caloric value of caprenin is 5 kcallg compared to the value of 9 kcal/g for other dietary triglycerides.
INTRODUCTION APRENIN* Is A TRIGLYCERIDE having both medium-chain fatty acids [MCFAs, i.e., C8:O (caprylic acid), C 1O:O C (capric acid)], and very long-chain fatty acids [VLCFAs, i.e., predominantly C22:O (behenic acid) with some C2O:O (arachidic acid) and C24:O (lignoceric acid)] randomly distributed on the same glycerol backbone. Caprenin has physical properties that make it suitable for use as a confectionery fat in soft candy, such as chocolate-flavored candy bars.
Caprenin has been shown to be qualitatively digested and absorbed like typical dietary triglycerides."' Caprenin triglycerides are hydrolyzed in the intestines, but the VLCFAs released are only partially absorbed.('.*' Net energy studies and fat balance studies in rats have shown that caprenin, when fed as the primary source of dietary fat, contributes only about 3-5 kcal of energy per gram compared to 9 kcal per gram supplied by corn oil or soybean (J.C. Peters, The Procter & Gamble Company, unpublished data). A part of the reduced calorie value can be ascribed to the lower inherent caloric density of MCFAs and their inefficient conversion into storage fat. (3) However, most of the reduction in usable energy of caprenin is attributed to the limited absorption of its VLCFA components. This report describes a human fat-balance study that was conducted to quantify the absorption of VLCFAs derived from a chocolate-flavored confection made with caprenin. There is little information in the literature concerning absorbability of VLCFAs in humans. Furthermore, our objective was to determine digestibility in the context of a typical balanced diet. The measured VLCFA absorption values were used to determine their metabolizable calorie contribution to caprenin.
The calorie content of the total caprenin triglyceride was calculated by summing the net calorie contribution of each of its component fatty acids and then accounting for glycerol (adding its heat of combustion) and water (subtracting its heat of formation). Since this calculation takes into account not only fat digestibility but also efficiency of metabolism of MCFAs, this approach is a refinement of the Atwater method'4' for determining the calorie content of a nutrient.
MATERIALS AND METHODS

Fat-balance study design
This was a single center, A-B-A-type within subjects crossover study conducted by Quincy Research Center, Kansas City, MO. Ten healthy adult males and 10 healthy adult females between the ages of 20 and 60 completed the study. Subjects were judged healthy by medical history, physical examination, and laboratory testing. Table 1 summarizes the characteristics of the subjects who completed our study.
The duration of the study was 19 days for each participant. During this time, subjects were inpatients on a metabolic ward. The initial 7 days of the study constituted a baseline washout period during which subjects were allowed ad libitum consumption of a well-balanced diet low in foods containing C20:0, C22:0, and C24:O. At the end of the washout period (days [5] [6] [7] and before consumption of the first chocolate-flavored test confection containing caprenin, all fecal material (including used toilet tissue) was collected for analysis of baseline excretion of VLCFAs. During days 5, 6, and 7, each of the 20 subjects provided at least two separate complete stool collections, which were analyzed individually.
For the 5 days after the washout period, subjects continued as inpatients, consuming the normal baseline diet low in VLCFAs. In addition, subjects consumed two 1.5-ounce caprenin chocolate-flavored confection bars (total of 24 g caprenin) each day. Subjects were allowed to consume a beverage with each test confection. The first bar was During the 5-day caprenin test confection consumption phase and for 7 days thereafter, subjects collected all fecal output and used toilet tissue in sealed containers. The additional 7-day posttreatment fecal collection period beyond the 5-day caprenin consumption phase was necessary to ensure quantitative recovery of all unabsorbed VLCFAs. During this final 7-day posttreatment washout phase, subjects did not consume any of the test material but continued to consume the baseline diet low in VLCFAs.
The baseline diet low in VLCFAkontent consisted of a7-day rotating menu constructed from foods low in peanut products (e.g., peanuts, peanut oil, peanut butter). Peanut products are the main source of VLCFAs (especially C22:O) in the typical American diet. Subjects consumed the same 7-day nutritionally balanced menu rotation on days 1-7, 8-14, and 15-19 of the study. Thus, the diet consumed during the initial 7-day pretreatment washout phase, the phase used to estimate baseline excretion of VLCFAs, and the diet eaten during the test confection consumption phase were the same. This allowed for more accurate estimation of net VLCFA excretion due to intake of the caprenin test confection.
The low VLCFA content of the 7-day baseline menu was verified by a registered dietitian. The food choices offered provided approximately 30-40% fat, 4540% carbohydrate, and 10-20% protein, all expressed as a percent of digestible energy.
Clinical experiences also were recorded on case report forms, a practice common to the conduct of any clinical study in which subjects are administered test material. Clinical experience reports that were volunteered by the subjects or elicited from subjects by nondirected questioning were collected and evaluated by the site physician of the study. Each experience was evaluated as slight, moderate, or marked in severity. The site physician also decided whether the experiences were attributable to the test product, concomitant therapy, a preexisting condition, or a new condition that developed while the subjects were on study.
Specimen collection, handling, and analysis
Feces and used toilet tissue were collected into hospital-grade plastic specimen containers. The sealed container was immediately frozen at -20°C and stored until analyzed. Stool samples collected and frozen during the final 3 days of the 7-day baseline pretreatment washout phase were processed individually. Fecal specimens from study days 8-16 were pooled and processed as a single homogeneous sample. Fecal specimens from study days 17, 18, and 19 were processed individually. The individual and pooled collections of feces were each homogenized in water. Measured portions of each homogenate were freeze-dried to a constant weight. The dry weight of each portion was recorded, and the total dry weights of the individual and pooled collections were calculated. A portion of each dry sample was analyzed for C20:0, C22:0, and C24:O fatty acid content by a gas chromatographic (GC) method that is described below.
Analytical method for fatty acid content in fecal fat
Because nonesterified C22:O has a melting point of 80°C and is poorly recovered using a standard chloroform: methanol extraction procedure (J.C. Peters, The Procter & Gamble Company, unpublished data), portions of dried fecal samples were subjected to a direct in siru methylation procedure, followed by organic extraction and gas chromatographic determination of total fatty acid methyl esters. Briefly, this procedure involves reacting dry feces with 2% (vh) sulfuric acid in methanol to convert fatty acids to methyl esters. The methylated fatty acids were then extracted, and the fatty acid methyl esters were separated on a capillary column coated with DB-wax stationery phase. The fatty acid esters were separated by chain length and degree of unsaturation. A split injection was made with flame ionization detection. A known quantity of purified C23:O methyl ester was added to the dried fecal sample before methylation, and a known amount of C21 :O methyl ester was added to the methyl ester extract before GC analysis to serve as internal and external standards, respectively. Recoveries of individual fatty acids in feces were calculated based on the recovery of the methyl ester of C23:O. All analyses of dry feces were run in duplicate, with average values reported.
Test product
The test material was a chocolate-flavored confection bar weighing approximately I .5 ounces (42.7 g) and containing approximately 12.05 g of caprenin as determined by direct analysis. The caprenin contained 3.9% C20:0,43.8% C22:0, and 0.7% C24:O by weight of the triglyceride as determined by direct analysis. Thus, each bar contained 0.47 g of C20:0, 5.28 g of C22:0, and 0.08 g of C24:O. The total caprenin-derived intake of these fatty acids by each subject over the 5-day test consumption period (10 bars) averaged about 4.7 g for C20:0, 52.8 g for C22:0, and 0.8 g for C24:O.
Analytical method for fatty acid composition of caprenin
Caprenin was converted to fatty acid ethyl esters by transesterification using sodium ethoxide, and fatty acid composition was determined according to the GC method previously described."' The results of this analysis are given in Table 2 .
Anutytical method for determination of levels of caprenin in the test product
In order to verify target levels of caprenin in the chocolate-flavored test material, caprenin and other lipids were extracted from the confection with 5050 (viv) hexane:ethyl ether. The extract was evaporated to dryness and weighed to determine the percent total lipid. A portion of the residue was taken and analyzed by a standard procedure known as carbon number p r~f i l e . '~) The average recovery of caprenin by this method was 99.2%, with an overall standard deviation of 0.62%.
Statistics
Correlations of VLCFA absorption as a function of gender were determined for individual fatty acids by Student's t-test. Correlations by age were determined based on linear regression analy~is.'~) All results were considered statistically significant if p < 0.05.
RESULTS
Subjects
Of the 21 subjects enrolled in the study, 20 completed the 19-day regimen. One male subject dropped out of the study during the prewashout phase for personal reasons. 
Absorption of C20:O, C22:O, and C24:O
The percent digestibility values for C20:0, C22:0, and C24:O are given in Tables 3,4 , and 5 . Absorption of these VLCFAs decreased with increasing chain length. Mean absorption of C20:O was 41.6%, C22:O was 28.8%, and C24:O was 14.8%. ForC24:0, several subjects had net output greater than total intake. This was probably the result of two factors: ( I ) extremely low and variable baseline C24:O intake on the low VLCFA diet and (2) the small amount of C24:O in the test confection. The amount of C24:O fed in the test confection was comparable to the magnitude of the variation in background C24:O excretion, producing negative values in some cases. In these cases, the percent C24:O absorbed was considered to be zero for purposes of calculating the overall average percent C24:O absorbed. Using this approach will overestimate C24:O absorption and caloric value of caprenin. Absorption results for one female subject were consistently high for all the VLCFA acids (about 70%). This subject was still excreting C20:0, C22:0, and C24:O fatty acids at the end of the 7-day posttreatment washout period. Thus, because of incomplete collection, the overall absorption values for all three VLCFAs (Tables 3,4, and 5 ) were overestimated in this subject.
There were no significant differences in VLCFA absorption when the data were analyzed by gender or age. For [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] (days [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] 
Clinical experiences
Because caprenin consumption leads to an increase in fecal fat output, it was of interest to collect information about any symptoms that might be related to consumption of the test material. Fourteen subjects reported a total of 41 clinical experiences during the 19-day period. Results presented in Table 6 provide a summary of the incidence of clinical experiences by study period and by severity. About 83% of those experiences recorded were evaluated as slight. Only 3 experiences were considered marked. One female subject reported a migraine headache on day I of the study. Two other females reported marked menstrual cramps, one on day 3 and one on day 8. Furthermore, there were an equal number of experiences in both the prewashout (n = 17) and the treatment periods (n = 16).
Clinical experiences also were evaluated as they related to body system. Results in Table 7 demonstrate that a wide variety of symptoms were reported, a pattern that is observed commonly during the conduct of metabolic ward studies. About 37% of the experiences were confined to the gastrointestinal system. These experiences included upset stomach, nausea, constipation/hard stool, diarrhea, and abdominal pain. Once again, this is consistent with the experience of conducting a metabolic ward study. Change in bowel habits is one of the most common symptoms reported in inpatient studies in which activity of the subjects is restricted and they are placed on a fixed diet. Because of the type of symptoms reported, the overall low degree of severity, and the equal distribution of experiences across both treatment and nontreatment phases of the study, none of the clinical experiences reported were considered to be related to the consumption of caprenin. aslight: The subject was aware of the sign or symptom but could easily tolerate it. Moderate: The discomfort caused by the sign or symptom was sufficient to interfere with normal activity of the subject. Marked The subject was incapacitated. 
DISCUSSION
The objective of the present study was to determine the caloric value of caprenin, a triglyceride that can substitute for cocoa butter and other confectionery fats in numerous commercial applications. Triglycerides generally provide about 9 kcal/g of fat based on the fact that most triglyceride-derived fatty acids are well absorbed. However, coefficients of absorption for saturated fatty acids 2 C20 in chain length have been shown in animals to be substantially less than typical saturated long-chain fatty acids S C18 in chain Based on this information and on caprenin's fatty acid composition, it was hypothesized that caprenin's caloric density in humans would be much less than typical dietary triglycerides. This hypothesis was tested in the present study by measuring directly the absorption of C2O:O, C22:0, and C24:O using the fat-balance technique.
Because most other methods for studying fat absorption (e.g., lymph cannulation) are impractical to apply to human studies, the fat-balance technique has remained the cornerstone method for determining fat absorption in humans." '-I4) Although various protocol designs can be employed successfully this technique is most powerful when the data are collected over a number of consecutive days so that equilibration is allowed to take place. It is also important that fat absorption is measured in what can be referred to as a "real world" context. Specifically, measuring fat absorption in relation to total dietary intake is essential, since many dietary constituents, such as minerals, protein, and fiber, can influence saturated fatty acid absorption." I ) However, human fat balance studies historically have been conducted by maintaining subjects on mixed diets that provide the test fat as the primary source of dietary fat calories." '-I4) This practice could lead to digestibility coefficients for fatty acids that may be artificially low and thus may not accurately reflect absorbability under more naturalistic dietary conditions. For example, the coefficient of absorption for caprenin-derived behenic acid is expected to follow the trend established by other behenoyl glycerides in that behenic acid absorption should be inversely proportional to its concentration in total dietary fat."' Thus, the appropriate condition for measuring the absorption of caprenin-derived VLCFAs is in the context in which caprenin will be consumed in the diet, namely, as a confectionery fat rather than the primary source of dietary fat. Based on all of these factors, the present study determined the absorption of caprenin-derived VLCFAs when the triglyceride was consumed as a component of a confectionery snack, and the snack was consumed two times per day as part of a balanced ad libitum diet.
The results of the present study demonstrate that the absorption of caprenin-derived C200, C22:O, and C24:O averaged 41.6%, 28.8%, and 14.8%, respectively. These results are consistent with those reported by other investigators who showed that absorption of long-chain fatty acids in humans('*] and very long-chain saturated fatty acids in animal^",^^'^^'^' was inversely proportional to saturated fatty acid chain length. Literature values for the absorption of behenic acid vary widely across species, with mean values ranging from approximately 1 1% for male and female thoracic duct-cannulated rats orally administered a bolus dose of caprenin'l) to about 55-60% for rats administered either a single oral dose of peanut oil or maintained on peanut oil-based diets."."' This range is explained partially based on the inverse relationship that exists between behenic acid uptake and concentration of behenic acid in total dietary fat.'') However, the wide range in the variability of coefficients of absorption of ABSORPTION AND CALORIC VALUE OF CAPRENIN IN HUMANS VLCFAs like C22:0, at a given concentration in the diet, also may historically reflect incomplete fecal recovery of the high melting fatty acid due to use of less than optimal extraction and derivitization methodology. This latter variable was minimized in the present study, since an analytical technique was employed that assumed complete recovery of VLCFAs.
It is clear from the present study that there is a great deal of variability between individual subjects in VLCFA uptake, even when levels of VLCFAs in the diet are fixed. Standard errors of the mean (SEM) for fatty acid absorption ranged from 3.7% for C20:O to 4.4% for C22:O. This degree of variability, however, is commonly seen in fat-balance s t u d i e~(~.~~'~~'~-'~) and can, in part, reflect biological variability due to such factors as differences between individuals in intraduodenal bile acid concentration, gastrointestinal transit time, lymph flow rates, and lipase efficiency.
In order to determine an overall caloric value for caprenin, we directly measured VLCFA absorption and combined the data with existing results on the use of medium-chain fatty acid (MCFA) energy. An alternative approach would have been to measure both VLCFA uptake and MCFA energy use in one human clinical study. However, this would have been impractical and inappropriate for determining the caloric content of a confectionery fat. To measure the inefficient use of caprenin-derived MCFA energy would have required that subjects subsist on diets that contained caprenin as the primary source of fat calories and, as discussed earlier, would have yielded an artificially low caloric value. Thus, it seemed reasonable to rely on MCFA literature data and combine these results with the digestibility of VLCFAs as determined in the present study.
For conventional dietary fats, which are those with C12 to C18 chain-length fatty acids (LCFAs), the average caloric density value is rhe familiar 9 kcalig. This is the rounded value for the average heat of combustion of conventional dietary fats (9.4 kcalig) times the average digestibility coefficient (0.94) for these fats.(4' These constants were applied to the present study since absorption of caprenin-derived LCFAs was not directly measured.
Medium-chain triglycerides (MCTs), which are comprised predominantly of C8:O and CI0:O fatty acids, are metabolized and used differently from long-chain triglycerides (LCTs), comprised of CI 2 4 1 8 fatty acids.",'6' MCTs are digested, absorbed, and transported directly to the liver, where they are rapidly oxidized and have a very low tendency to deposit as body fat. Animal studies have shown that MCT diets support a reduced rate of weight gain compared to LCT diets, and the reduced weight gain predominantly reflects a reduction in fat deposit i~n . ( '~-~~' Based on these published animal studies, we have calculated an average net energy coefficient for MCTs to be about 0.86 relative to 1 .O for LCTs.
Although studies of body energy deposition cannot be carried out in humans, at least part of the mechanism of reduced energy deposition for MCTs is due to an enhanced thermic effect of food after MCT consumption relative to LCT consumption. Differences in thermic effects of MCTs and LCTs have been measured in including lean and obese subjects. These studies show that humans experience a reduced net energy effect of at least 6-10% for MCTs relative to LCTs based on an increased thermic effect alone. However, the difference in thermic effect determined in the human studies does not provide the complete measure of the overall differences in efficiencies of use between MCTs and LCTs. This is, in part, because the studies were not carried out over a sufficient length of time so that the MCT effect could return to baseline. The more definitive studies have been those conducted primarily in rats, since growth and carcass energy can be determined directly.
Using the approach outlined in the present report, the physiological fuel value (caloric value) of caprenin, or any fat, can be calculated by summing the net energy contribution of each of its component fatty acids and then accounting for glycerine (adding its heat of combustion) and water (subtracting its heat of formation). Based on an average molecular weight of 685 for caprenin, the calculated caloric density for caprenin is 5 kcalig, as shown in Table 8 . This represents a 44% reduction in calories in comparison to other dietary triglycerides. 
